CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below.
All CIRM Grants
Search Filters »
Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
Calibr |
Peter G Schultz |
Preclinical Development Awards |
Development of a Chondrogenic Drug Candidate Targeting Cartilage-residing Mesenchymal Stem Cells for the Treatment of Osteoarthritis |
$2,306,703 |
Scripps Health |
Dr. Darryl D. D’Lima |
Preclinical Development Awards |
Embryonic Stem Cell-Derived Chondroprogenitor Cells to Repair Osteochondral Defects |
$7,660,211 |
University of California, Davis |
Dr. Roslyn Rivkah Isseroff |
Preclinical Development Awards |
Scaffold for dermal regeneration containing pre-conditioned mesenchymal stem cells to heal chronic diabetic wounds |
$4,620,144 |
University of California, Irvine |
Dr. Leslie M Thompson |
Preclinical Development Awards |
A hNSC Development Candidate for Huntington’s Disease |
$4,951,623 |
Stanford University |
Dr. Matthew H Porteus |
Preclinical Development Awards |
Pre-clinical development of gene correction therapy of hematopoietic stem cells for SCID-X1 |
$874,877 |
University of California, Davis |
Dr. Diana L. Farmer |
Preclinical Development Awards |
Placental Stem Cells for the In Utero Treatment of Spina Bifida |
$2,182,146 |
Salk Institute for Biological Studies |
Dr. David R Schubert |
Preclinical Development Awards |
Human Stem-Cell Based Development of a Potent Alzheimer’s Drug Candidate |
$1,664,885 |
ViaCyte, Inc. |
Howard Foyt |
Accelerated Development Pathway I |
Clinical Development of a Cell Therapy for Diabetes |
$8,783,852 |
University of California, San Diego |
Catriona Jamieson |
Alpha Stem Cell Clinics |
Alpha Stem Cell Clinic for the Development of Regenerative Therapies |
$8,679,137 |
University of California, Los Angeles |
John S. Adams |
Alpha Stem Cell Clinics |
UCLA-UCI Alpha Stem Cell Clinic (ASCC) Consortium |
$8,680,000 |
City of Hope, Beckman Research Institute |
Prof. John A. Zaia |
Alpha Stem Cell Clinics |
The Innovation-Alpha Clinic for Cellular Therapies (I-ACT) – A Program for the Development and Delivery of Innovative Cell-based Treatments and Cures for Life-threatening Diseases. |
$8,416,531 |
University of California, Davis |
Dr. J. Kent Leach |
Tools and Technologies III |
Multi-modal technology for non-destructive characterization of bioengineered tissues |
$1,574,151 |
University of Southern California |
Dr. Qilong Ying |
Tools and Technologies III |
Embryonic stem cell-based generation of rat models for assessing human cellular therapies |
$1,326,979 |
Stanford University |
Sarah Heilshorn |
Tools and Technologies III |
Injectable Hydrogels for the Delivery, Maturation, and Engraftment of Clinically Relevant Numbers of Human Induced Pluripotent Stem Cell-Derived Neural Progenitors to the Central Nervous System |
$1,347,767 |
Stanford University |
Dr. James C. Dunn Dr. |
Tools and Technologies III |
Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction |
$772,098 |
University of California, Los Angeles |
Dr. James C. Dunn Dr. |
Tools and Technologies III |
Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction |
$1,044,423 |
University of California, San Diego |
Dr. Shyni Varghese |
Tools and Technologies III |
Technologies to improve in vivo function of transplanted stem cells |
$1,373,683 |
University of California, San Diego |
Shaochen Chen |
Tools and Technologies III |
Development of 3D Bioprinting Techniques using Human Embryonic Stem Cells Derived Cardiomyocytes for Cardiac Tissue Engineering |
$1,368,264 |
University of California, Irvine |
Dr. Mathew Mark Blurton-Jones |
Tools and Technologies III |
Optimizing the differentiation and expansion of microglial progenitors from human pluripotent stem cells for the study and treatment of neurological disease. |
$1,147,596 |
University of California, Davis |
Dr. Laura Marcu |
Tools and Technologies III |
Multimodal platform combining optical and ultrasonic technologies for in vivo nondestructive evaluation of engineered vascular tissue constructs |
$1,834,350 |
University of Southern California |
Dr. Paula M. Cannon |
Tools and Technologies III |
Site-specific gene editing in hematopoietic stem cells as an anti-HIV therapy |
$1,495,665 |
City of Hope, Beckman Research Institute |
Joseph D Gold |
Tools and Technologies III |
Development of a scalable, practical, and transferable GMP-compliant suspension culture-based differentiation process for cardiomyocyte production from human embryonic stem cells. |
$891,518 |
Stanford University |
Dr. Fan Yang PhD |
Tools and Technologies III |
Injectable Macroporous Matrices to Enhance Stem Cell Engraftment and Survival |
$1,434,235 |
University of California, Berkeley |
Dr. David V. Schaffer |
Tools and Technologies III |
Engineered Biomaterials for Scalable Manufacturing and High Viability Implantation of hPSC-Derived Cells to Treat Neurodegenerative Disease |
$1,239,276 |
Stanford University |
Dr. Joseph C. Wu |
Tools and Technologies III |
Macaca mulatta as advanced model for predictive preclinical testing of engineered cardiac autografts and allografts |
$1,689,744 |
Stanford University |
Dr. Anthony E. Oro |
Tools and Technologies III |
A Chromatin Context Tool for Predicting iPS Lineage Predisposition and Tissue Graftability |
$1,391,125 |
University of California, Los Angeles |
Dr. Hanna Mikkola |
Tools and Technologies III |
A suite of engineered human pluripotent stem cell lines to facilitate the generation of hematopoietic stem cells |
$1,382,400 |
University of California, San Francisco |
Dr. Andrew D. Leavitt MD |
Tools and Technologies III |
Small molecule tools and scale-up technologies to expand human umbilical cord blood stem and progenitor cells for clinical and research use |
$1,416,600 |
Stanford University |
Professor Irving L Weissman MD |
Tools and Technologies III |
Identification and isolation of transplantable human hematopoietic stem cells from pluripotent cell lines; two steps from primitive hematopoiesis to transplantable definitive cells, and non-toxic conditioning of hosts for hematopoeitic stem cell transp… |
$1,271,952 |
University of California, Los Angeles |
Dr. Carla M. Koehler |
Tools and Technologies III |
A small molecule tool for reducing the malignant potential in reprogramming human iPSCs and ESCs |
$1,283,900 |
University of Southern California |
Dr. Toshio Miki |
Tools and Technologies III |
Development of a clinical-grade extracorporeal liver support system using human induced pluripotent stem cell-derived hepatic cells |
$1,257,011 |
Scripps Research Institute |
Dr. Jeanne F Loring |
Tools and Technologies III |
User-friendly predictive molecular diagnostic assays for quality control of stem cell derivatives for transplantation and drug discovery |
$1,728,390 |
University of California, Los Angeles |
Leif Havton |
Tools and Technologies III |
Development of a Relevant Pre-Clinical Animal Model as a Tool to Evaluate Human Stem Cell-Derived Replacement Therapies for Motor Neuron Injuries and Degenerative Diseases |
$1,308,711 |
University of California, Davis |
Randi Hagerman |
Conference |
Pathways of Neurodevelopmental Disorders (C8) |
$29,939 |
Stanford University |
Dr. Joseph C. Wu |
Conference |
Cardiovascular Tissue Engineering Symposium |
$25,000 |
Ocular Research Symposia Foundation, Inc. |
Dr. Gerald Chader |
Conference |
SIGHT RESTORATION THROUGH STEM CELL THERAPY |
$20,000 |
University of Southern California |
Qing Liu-Michael |
Conference |
USC/UCSF/UCLA Tri-Institutional Stem Cell Retreat |
$5,000 |
Vitalant Research Institute |
Dr. Shibani Pati |
Conference |
Cellular Therapies in Trauma and Critical Care Medicine: Forging New Frontiers |
$40,000 |
City of Hope, Beckman Research Institute |
Fouad Kandeel |
Conference |
15th Annual Rachmiel Levine Diabetes and Obesity Symposium |
$20,000 |
University of California, Davis |
Dr. Alice F Tarantal |
Conference |
13th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases |
$10,000 |
Sanford Consortium for Regenerative Medicine |
Dr. Edward Holmes |
Conference |
Stem Cell Meeting on the Mesa |
$40,000 |
Gordon Research Conferences |
Leonard I. Zon |
Conference |
2015 Gordon Research Conference: Stem Cells & Cancer |
$20,000 |
University of California, San Francisco |
Dr Diana Jean Laird |
Conference |
The 2014 Santa Cruz Developmental Biology Meeting |
$3,000 |
University of California, San Diego |
Shu Chien |
Conference |
10th Annual UC Systemwide Bioengineering Symposium |
$8,000 |
University of California, San Diego |
Shu Chien |
Conference |
The 14th UC Systemwide Bioengineering Symposium |
$5,000 |
University of California, San Francisco |
Dr. Emmanuelle Passegue |
Conference |
CA-HSCI 1st Generation Stem Cell PI Meeting |
$20,000 |
University of California, San Francisco |
Dr. Ophir Klein MD, PhD |
Conference |
Stem Cells Craniofacial Development and Disease |
$4,500 |
University of California, San Diego |
Prof. John M. Ravits |
Conference |
Cell Therapy for amyotrophic Lateral Sclerosis (ALS) -Testing the Limits: What should we use as preclinical standards of clinical trials? |
$7,193 |
Children’s Neurobiological Solutions (CNS) Foundation |
Alex Richmond |
Conference |
The Best Next Steps: Setting a Path for Advancing Pediatric Neurology |
$10,000 |
Vitalant Research Institute |
Shibani Pati |
Conference |
Cell Therapies in Trauma and Critical Care: Barriers in Translation from Pre-clinical to Clinical Development |
$18,440 |